title: Quantitative analysis of glycation patterns in human serum albumin using 16O/18O-labeling and MALDI-TOF MS.
abstract: BACKGROUND
  The glycation of human serum albumin (HSA) during diabetes can affect the ability of this protein to bind drugs and small solutes in blood. This study describes the use of (16)O/(18)O-labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry to compare the levels of modification that occur throughout HSA under various glycation conditions in vitro. These quantitative studies build on a recent report that has identified the early and advanced glycation products that are formed on such samples of HSA.
  
  
  METHODS
  Glycated HSA samples were prepared by incubating 42 g/l HSA with 0 to 15 mmol/l glucose at pH 7.4 and 37°C for up to 5 weeks. A control HSA sample was digested in (16)O-enriched water and glycated HSA samples were digested in the presence of (18)O-enriched water. These 2 types of samples were then mixed and the amounts of (16)O- vs. (18)O-labeled peptides were measured to determine the levels of modification that were occurring throughout HSA.
  
  
  RESULTS
  The largest levels of modification occurred in residues 101-119, 1-10 or 42-51, 87-100, 360-372, 521-531, and 275-286 of HSA after 2 weeks of glycation, and in residues 21-41, 1-10 or 42-51, 521-531, 82-93, and 146-160 after 5 weeks of glycation. Some of these regions contained the N-terminus, K199, K439, and K525, which have been previously identified as major glycation sites on HSA. The glycation pattern of HSA was dominated by early glycation products (e.g., fructosyl-lysine) after a reaction period of 2 weeks for mildly glycated HSA, while advanced glycation end products became more prominent at longer reaction times.
  
  
  CONCLUSIONS
  The time course of the observed modifications indicated that the pattern of glycation products changed as HSA was incubated over longer periods of time with glucose. Several regions found to have significant levels of modification were at or near the major drug binding regions on HSA. These results explain why the interaction of some drugs with HSA has been observed to vary with the level of glycation for this protein.
authors: Department of Chemistry, University of Nebraska, Lincoln, NE, United States.
authors: Omar S
authors: OS
authors: Barnaby
authors: Ronald L
authors: RL
authors: Cerny
authors: William
authors: W
authors: Clarke
authors: David S
authors: DS
authors: Hage
references: Diabetologia. 1995 Sep;38(9):1076-81
references: 8591822
references: Trends Cardiovasc Med. 1996 Jul;6(5):163-8
references: 21232291
references: J Mol Graph. 1996 Feb;14(1):33-8, 27-8
references: 8744570
references: Biochem J. 1989 Aug 1;261(3):871-8
references: 2803249
references: Gerontology. 2009;55(1):73-81
references: 18802325
references: Biopharm Drug Dispos. 1997 Dec;18(9):791-801
references: 9429743
references: J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Oct 15;878(28):2775-81
references: 20829128
references: Mass Spectrom Rev. 2006 Sep-Oct;25(5):775-97
references: 16625652
references: Clin Chim Acta. 2011 Jan 30;412(3-4):277-85
references: 21034726
references: J Biol Chem. 1986 Oct 15;261(29):13542-5
references: 3759977
references: Biochem J. 2002 May 15;364(Pt 1):1-14
references: 11988070
references: Ann N Y Acad Sci. 2005 Jun;1043:260-6
references: 16037246
references: J Biol Chem. 2005 Feb 18;280(7):5724-32
references: 15557329
references: J Pharm Biomed Anal. 2011 Jan 25;54(2):426-32
references: 20880646
references: Electrophoresis. 1999 Dec;20(18):3551-67
references: 10612281
references: Protein Eng. 1999 Jun;12(6):439-46
references: 10388840
references: JAMA. 1999 Jun 2;281(21):2005-12
references: 10359389
references: J Pharmacol Exp Ther. 2006 May;317(2):667-75
references: 16410405
references: Protein Pept Lett. 2007;14(1):13-8
references: 17266645
references: Electrophoresis. 1996 May;17(5):945-53
references: 8783021
references: J Biol Chem. 1984 Mar 25;259(6):3812-7
references: 6706980
references: J Gerontol. 1990 Jul;45(4):B105-11
references: 2195101
references: J Pharm Biomed Anal. 2010 Nov 2;53(3):811-8
references: 20537832
references: Clin Chim Acta. 2007 Oct;385(1-2):48-60
references: 17707360
references: Anal Bioanal Chem. 2010 Jul;397(6):2349-56
references: 20496030
references: Rapid Commun Mass Spectrom. 2001;15(24):2456-65
references: 11746917
references: Anal Chem. 2006 Dec 1;78(23):7967-77
references: 17134129
references: Clin Chem. 1995 Nov;41(11):1654-61
references: 7586558
references: Biochem J. 1999 Nov 15;344 Pt 1:109-16
references: 10548540
references: Diabetes Care. 2003 Jan;26 Suppl 1:S5-20
references: 12502614
references: Anal Biochem. 2006 Feb 15;349(2):229-41
references: 16356458
references: Clin Chim Acta. 2010 Aug 5;411(15-16):1102-10
references: 20394739
references: J Biol Chem. 1992 May 25;267(15):10211-4
references: 1587810
references: Ann N Y Acad Sci. 2005 Jun;1043:111-7
references: 16037229
references: Pharmacol Rep. 2005;57 Suppl:156-68
references: 16415497
references: Mol Cell Proteomics. 2010 Mar;9(3):579-92
references: 19955080
references: J Proteome Res. 2009 Feb;8(2):754-69
references: 19093874
references: J Clin Invest. 1997 Aug 15;100(4):847-54
references: 9259584
references: Rapid Commun Mass Spectrom. 2004;18(8):869-76
references: 15095355
references: J Mass Spectrom. 2005 Jul;40(7):969-72
references: 15768376